Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multi-Center Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-Fluorouracil (5-FU) Plus Bevacizumab Versus Leucovorin and 5-FU Plus Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma

NCT00337389 is registered in ClinicalTrials.gov with Mast Therapeutics, Inc. as lead sponsor.

NCT NCT00337389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00337389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multi-Center Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-Fluorouracil (5-FU) Plus Bevacizumab Versus Leucovorin and 5-FU Plus Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma
Lead sponsor
Mast Therapeutics, Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
May 31, 2006
Completion date
Not reported
Enrollment
1,200 (estimated)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, metastatic colorectal cancer, rectal cancer